secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001104659-23-079823
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Deborah Birx resigns from Innoviva board to become CEO of majority-owned Armata Pharmaceuticals
--------------------------------------------------------------------------------

- Deborah L. Birx resigned from the Board and Audit Committee effective July 10, 2023.
- She accepted the CEO position at Armata Pharmaceuticals, a majority-owned Innoviva subsidiary.
- Resignation was not due to any disagreement with the Company's operations, policies, or controls.
- No other Board changes or disagreements disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923079823/0001104659-23-079823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923079823/tm2320969d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer